Hypoxic pulmonary hypertension (HPH) is a condition characterized by increased pulmonary artery pressure caused by prolonged exposure to a hypoxic environment. It frequently occurs among individuals residing at high altitudes and those with chronic obstructive pulmonary disease.
Wall Street was sorting through two batches of news from Jasper Therapeutics Inc., which made public positive data from the phase Ib study called Etesian with KIT-targeting briquilimab in adults with allergic asthma, while making known the outcome of a probe into the phase Ib/II Beacon study with the same drug in chronic spontaneous urticaria.
Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic pulmonary fibrosis, cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH), interstitial lung diseases, systemic scleroderma (systemic sclerosis) and systemic lupus erythematosus.
